ArticleCase reports in oncology

Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report.

Ryota Tatsuhige et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.